Allogene Therapeutics
South San Francisco, CA
Allogene Therapeutics, Inc. operates as a biotechnology company. The Company develops allogeneic chimeric antigen receptor T-cell therapy for the treatment of blood cancers and solid tumors. Allogene Therapeutics serves patients in the State of California.
allogene.comCompany Details
Founded
- 2017
Employees
- 226 employees
Raised
- $891,770,368
Headquarters Location
- South San Francisco, CA
Public
- Yes
Acquired
- No
CEO
David Chang
Founders
- Arie BelldegrunJoshua KazamDavid Chang
Company Collections
These are collections Allogene Therapeutics is a part of. Click on the collection name to view similar companies.
Allogene Therapeutics' Industries
Allogene Therapeutics Headquarters Location
210 E Grand Av, South San Francisco, CA 94080
Total Amount Raised: $891,770,368
Allogene Therapeutics Funding Rounds
Post Ipo Equity
$110,000,000
Post Ipo Equity
$250,000,000
Convertible Note
$120,000,000
Convertible Note Investors
Perceptive AdvisorsDeerfield Capital ManagementFidelity InvestmentsJennison AssociatesFranklin Resources, Inc.T. Rowe PriceSurveyor CapitalAvoro Capital AdvisorsCowen Investment ManagementSeries A
$411,770,409
Series A Investors
TPGVida VenturesPfizerTwo RiverBellco CapitalGilead SciencesIPO
Unknown
Funding info provided by Diffbot.
Allogene Therapeutics Reviews
0 out of 5 stars
Based on 0 reviews
Review data
Share your thoughts
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Allogene Therapeutics.